Ron Squarer

Ron Squarer has been a member of the board of directors of Travere Therapeutics, Inc. since 2017. Mr. Squarer has extensive commercial, development, and executive leadership expertise from a career that spans more than two decades in the biopharmaceutical industry. He served as chief executive officer and a member of the board of directors of Array BioPharma, Inc. from 2012 until its acquisition by Pfizer in 2019. Prior to this, Mr. Squarer held positions of increasing responsibility with Hospira Inc., a global pharmaceutical and medical device company, most recently serving as senior vice president, chief commercial officer, where he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as senior vice president, global corporate and business development when Mayne was sold to Hospira in 2007. Prior to Mayne Pharma, Mr. Squarer held senior management roles at both Pfizer, Inc., and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the US and Europe. He currently serves as a member of the board of directors for Deciphera Pharmaceuticals and as the chairman of the board at ADC Therapeutics. Mr. Squarer holds an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.